Hypogonadism in a Patient with a Mutation in the Luteinizing Hormone Beta-Subunit Gene by Valdes Socin, Hernan Gonzalo et al.




















Hypogonadism in a Patient with a Mutation
in the Luteinizing Hormone Beta-Subunit Gene
 
Hernán Valdes-Socin, M.D., Roberto Salvi, Ph.D., Adrian F. Daly, M.B., M.Sc., 
Rolf C. Gaillard, M.D., Pascale Quatresooz, M.D., Pierre-Marie Tebeu, M.D., 
François P. Pralong, M.D., and Albert Beckers, M.D., Ph.D.
 
From the Departments of Endocrinology
(H.V.-S., A.F.D., A.B.) and Dermatopathol-
ogy (P.Q.), Centre Hospitalier Universitaire
de Liège, Domaine du Sart-Tilman, Liege,
Belgium; the Division of Endocrinology,
Diabetology, and Metabolism, University
Hospital, Lausanne, Switzerland (R.S.,
R.C.G., F.P.P.); and the Department of
Obstetrics and Gynecology, University of
Yaoundé, Cameroon (P.-M.T.). Address re-
print requests to Dr. Beckers at the De-
partment of Endocrinology, Centre Hospi-
talier Universitaire de Liège, Domaine du
Sart-Tilman, 4000 Liege, Belgium, or at
albert.beckers@chu.ulg.ac.be.
Drs. Valdes-Socin and Salvi contributed
equally to this article.
N Engl J Med 2004;351:2619-25.
 
Copyright © 2004 Massachusetts Medical Society.
 
A 30-year-old man who presented with delayed puberty and infertility was found to have
hypogonadism associated with an absence of circulating luteinizing hormone. The pa-
tient had a homozygous missense mutation in the gene that encodes the beta subunit
of luteinizing hormone (Gly36Asp), a mutation that disrupted a vital cystine knot motif
and abrogated the heterodimerization and secretion of luteinizing hormone. Treatment
with human chorionic gonadotropin increased circulating testosterone, promoted virili-
zation, and was associated with the appearance of normal spermatozoa in low concen-
trations. This case illustrates the important physiological role that luteinizing hormone
 
plays in male sexual maturation and fertility.
 
exual maturation and fertility in men requires normal testicu-
 
lar development, which is governed by chorionic gonadotropin in utero and
thereafter by luteinizing hormone and follicle-stimulating hormone. The most
frequent causes of hypogonadotropic hypogonadism are abnormalities affecting the se-
cretion of hypothalamic gonadotropin-releasing hormone or pituitary gonadotropic
hormones; these disorders result in delayed puberty and infertility. Genetic mutations
that interfere with the signaling of gonadotropic hormones or their interactions with




The glycoprotein hormones luteinizing hormone, follicle-stimulating hormone, cho-
rionic gonadotropin, and thyrotropin share a common alpha subunit but have unique





 Naturally occurring inactivating mutations of the gene encoding
the alpha subunit of glycoprotein hormone have not been described, but rare mutations
in the beta-subunit sequence that produce truncated or abnormally folded proteins have
been reported. Mutations in the beta subunit of follicle-stimulating hormone cause hy-




 whereas delayed puberty or infertility









the beta subunit of follicle-stimulating hormone. There has been only one report of a
patient with an inactivating mutation in the luteinizing hormone beta subunit that




That patient had a missense mutation that prevented the binding of heterodimeric lute-
inizing hormone to its receptor.
We describe a man with delayed puberty and infertility due to an isolated deficiency
in luteinizing hormone. The patient had a novel homozygous missense mutation in the
gene encoding the luteinizing hormone beta subunit, which prevented the heterodimer-
summary
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ization and secretion of luteinizing hormone and
abolished its biologic activity.
A 30-year-old man from Cameroon was referred for
investigation of sexual infantilism. He was 191 cm
tall, weighed 100 kg, and had an arm span of 205
cm. He had a eunuchoid habitus, gynecomastia, and
a juvenile voice. Penile length was 4 cm, and testic-
ular volume was 8 ml. Scant, normally distributed
pubic hair had been present since his late teens. No
family members were available for genetic testing,
but no case of infertility was reported among the pa-
tient’s immediate and second-degree relatives. Con-
sanguinity could not be definitively ruled out.
The results of initial laboratory tests were as fol-
lows: an undetectable luteinizing hormone level
(less than 0.2 mIU per milliliter; normal range, 2.0
to 10.0), an elevated follicle-stimulating hormone
level (23 mIU per milliliter; normal range, 1.0 to
8.0), a low testosterone level (0.3 ng per milliliter
[1.0 nmol per liter]; normal range, 2.5 to 10.0 [8.7 to
34.7]); a low serum dihydrotestosterone level (73 ng
per liter; normal range, 200 to 1000), and a low de-
hydroepiandrosterone sulfate level (851 µg per li-
ter; normal range, 900 to 3700). The patient had
normal or low-normal levels of inhibin B (156 ng
per liter; normal range, less than 400), progesterone
(0.1 µg per liter; normal range, 0.1 to 0.7), estradiol
(26 ng per liter [95.4 pmol per liter]; normal range,
10 to 70 [36.7 to 257.0), and chorionic gonadotro-
pin beta subunit (less than 2.0 IU per liter; normal
range, 0 to 5.0). Ninety minutes after the intrave-
nous administration of gonadotropin-releasing
hormone (100 µg), the patient’s level of follicle-
stimulating hormone rose from 23 to 48 mIU per
liter; however, no luteinizing hormone was detect-
ed. Magnetic resonance imaging of the brain and
pituitary gland showed no abnormalities.
A specimen from a testicular biopsy showed hy-
poplastic seminiferous tubules with a predomi-
nance of Sertoli cells (Fig. 1A). Spermatogenesis
was evident, though greatly reduced. A scant num-
ber of spermatozoa were noted (Fig. 1B). Leydig
cells were visible on staining with hematoxylin and
eosin (Fig. 1C). Interstitial microcalcifications were
present.
A diagnosis of hypogonadotropic hypogonad-
ism due to an isolated luteinizing hormone deficien-
cy was made. The patient was treated initially with
case report
 
Figure 1. Testicular-Biopsy Specimen from the Patient 
with Hypogonadism and a Mutation in the Luteinizing 
Hormone Beta-Subunit Gene (Hematoxylin and 
Eosin).
 
Panel A shows representative hypoplastic seminiferous 
tubules (T) with predominant Sertoli cells (arrow), 
a thickened basement membrane (BM), and a fi-
broedematous interstitium (I). Multiple stages of sper-
matogenesis are evident in the specimen, although at a 
greatly reduced level. Panel B shows the section with the 
greatest differentiation. The thickness of the germinal 
layer is reduced (arrows), and only scattered spermato-
zoids are present (arrowhead). Panel C shows two clus-
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intramuscular testosterone (Sustanon 250, Orga-
non) at a dose of 1 ml every three weeks. After two
weeks, the level of serum follicle-stimulating hor-
mone normalized (3.5 mIU per milliliter), and se-
rum testosterone was 3.5 ng per milliliter (12.1
nmol per liter). During the next 12 weeks, testoster-
one induced penile growth to 8 cm and masculin-
ization, but testicular volume remained unchanged,
and ejaculate was azoospermic. At the end of three
months, testosterone treatment was discontinued,
and treatment with chorionic gonadotropin (1500
IU administered intramuscularly three times a week
for one month, then 5000 IU given weekly) was in-
stituted, which maintained testosterone secretion
and increased testicular volume to 14 ml. After 12
months of therapy with human chorionic gonado-
tropin, the patient remained oligospermic (1000
spermatozoa per milliliter), though the spermato-




An immunoassay system (Elecsys, Roche Diagnos-
tics) was used to measure luteinizing hormone,
follicle-stimulating hormone, testosterone, dehy-
droepiandrosterone sulfate, progesterone, and es-
tradiol. The beta subunit of human chorionic go-
nadotropin, inhibin B, and dihydrotestosterone
were measured with the use of immunoassays (CIS
Bio International, Serotec, and Intertech, respective-
ly). The interassay coefficient of variation for dihy-
drotestosterone was 18.6 percent or less. All other
interassay and intrassay coefficients of variation
were 7 percent or less. The absence of luteinizing
hormone was confirmed with the use of two sepa-
rate immunoassays, one that is specific for epitopes
on both the assembled alpha–beta luteinizing hor-
mone heterodimer and on the luteinizing hormone
beta subunit alone (Roche Diagnostics) and one
that is specific for the luteinizing hormone beta
subunit alone (Biocode-Hycel). The lower limit of
detection for both assays was 0.1 mIU per milliliter;
neither assay cross-reacted with other glycoprotein
hormones.
 
dna sequencing and analysis
 
Genomic DNA was extracted from leukocytes with
the use of commercially available reagents (Nucleon
BACC2, Amersham Biosciences). DNA obtained
from one normal volunteer was used as a wild-type
control. A 1082-bp amplicon containing the com-
plete luteinizing hormone beta-subunit gene was
recovered by polymerase-chain-reaction (PCR) assay
and sequenced in sense and antisense directions
with the use of an automated sequencer. To avoid
coamplification of the homologous chorionic go-
nadotropin beta-subunit gene or pseudogenes, the
primers contained at least one last nucleotide that
was mismatched at the 3' end. Alignments and com-
parisons between sequences were made with the
use of two software programs (BestFit and PileUp
from the GCG Wisconsin Package, Accelrys). To test
whether any mutation that was discovered repre-
sented a polymorphism, chromosomes from 162
ethnically matched people from Cameroon were an-
alyzed. DNA was extracted with the QIAamp DNA
Blood Mini Kit (Qiagen) and was then subjected to







functional analysis of mutant beta 
subunit
 
All expression vectors for this study were con-
structed with the use of the backbone of pcDNA3
(Stratagene), into which the coding sequences of
the proband and wild-type beta subunits and the
common alpha subunit of human glycoprotein
hormone were cloned. Since the insertion of poly-
peptides at the C-terminals of human glycoprotein





 a tag (a 6 histidine residue
[6xHis] for beta subunits and the V protein of sim-
ian virus 5 [V5] for the alpha subunit) was inserted
in-frame into the C-terminal coding sequence just
before the natural stop codon.
Plasmid constructs were verified by sequencing.
Human embryonic kidney 293T cells were transfect-
ed with expression vectors (15 µg per plasmid) in
10-cm dishes, with the use of the calcium phosphate
technique. Cell lysates were prepared 48 hours after
transfection, and Western blotting or immunopre-
cipitation studies were performed. For immuno-
precipitation studies, cell lysates (500 µg) were in-
cubated with either 5 µg of an anti-V5 monoclonal
antibody (Invitrogen) or 5 µg of an anti-6xHis mono-
clonal antibody (PharMingen) and then treated with
protein G Sepharose (Amersham Biosciences). Im-
munoprecipitates were separated by 15 percent so-
dium dodecyl sulfate–polyacrylamide-gel electro-
phoresis (SDS-PAGE) under reducing conditions,
electroblotted onto a polyvinylidenedifluoride mem-
methods
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brane, and probed with either an anti-6xHis anti-
body or an anti-V5 antibody. Blots were visualized
with the use of an enhanced chemiluminescence
system (ECL, Amersham Biosciences). The same
SDS-PAGE conditions and antibodies were used for
Western blotting. Further details on standard plas-
mid cloning and conditions of the PCR assay are
available on request.
The patient provided written informed consent
for the study. Approval was obtained from the insti-
tutional review board of Lausanne University Hos-
pital in Switzerland for all genetic and molecular
investigations that were undertaken. The 162 eth-
nically matched subjects (324 chromosomes) and
the normal male Swiss volunteer who provided DNA
for use as the wild-type control all provided in-
formed written consent as approved by the institu-
tional review board.
The patient’s karyotype was 46,XY. Analysis of his
luteinizing hormone beta-subunit gene sequence
revealed a single-nucleotide guanine-to-adenine
substitution in the terminal part of exon 2 (Fig. 2A).
This homozygous missense mutation induced a
substitution of aspartic acid for glycine at position
36 of the luteinizing hormone beta-subunit se-
quence (Gly36Asp). All 324 ethnically matched con-
trol chromosomes had the normal, wild-type se-
quence, confirming that the mutation was not a
polymorphism in this population (Fig. 2B).
Western blots of transiently transfected 293T
cells showed that the mutated luteinizing hormone
beta-subunit protein was synthesized correctly (Fig.
3A). The Gly36Asp substitution involved a highly
conserved glycine residue located in the cystine knot
motif of the luteinizing hormone beta subunit. We
hypothesized that this mutation might produce the
observed phenotype by interfering with alpha–beta
heterodimerization of luteinizing hormone. Immu-
noprecipitates from 293T cells cotransfected with
wild-type luteinizing hormone beta subunit showed
coprecipitation of the alpha and beta subunits, in-
dicating that heterodimerization had occurred (Fig.
3B). In contrast, immunoprecipitates from cells
cotransfected with the proband’s mutated luteiniz-
ing hormone beta subunit showed no beta-subunit
band, confirming that the Gly36Asp mutation pre-
vented alpha–beta heterodimerization. As expected,
cells that were mock-transfected (transfected with
a control construct) did not show any immunopre-
cipitation band (mock lane in Fig. 3B). Correct pro-
duction of the V5-tagged alpha subunit in cotrans-
fected cells was verified by Western blotting with an
anti-V5 antibody (Fig. 3C). To confirm the results
of the immunoprecipitation studies, we performed
a reciprocal-format experiment, in which cell ex-
tracts were immunoprecipitated with anti-6xHis an-
tibody followed by anti-V5 immunodetection. The
alpha subunit could be detected only in extracts of




Figure 2. Mutation in the Luteinizing Hormone Beta-Subunit Gene.
 
The Gly36Asp mutation occurred in exon 2 in the codon for the glycine residue of the cystine knot CAGYC motif (Panel A). 
The positions of the forward primer (FP) and the reverse primer (RP) that were used in the PCR assay to recover the ge-




I site. Panel B shows a representative gel analysis that was 
used to screen ethnically matched genomic amplicon samples for polymorphisms. Lanes 2 and 3 contain two wild-type 
amplicons obtained from ethnically matched samples; lane 4 contains the proband’s mutated amplicon. Lane 1 con-
tains a size marker.








Cys CysAla Gly Tyr
Cys CysAla Asp Tyr
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The development of Leydig cells and steroidogene-
sis are controlled by activation of luteinizing hor-
mone receptors both before and after birth by pla-
cental chorionic gonadotropin and pituitary lute-
inizing hormone, respectively. The beta subunits of
these hormones share more than 80 percent se-
quence homology and originate from a contiguous





fetal life, chorionic gonadotropin stimulates the
growth of primordial Leydig cells and the produc-





 Mutations in the luteinizing hor-
mone receptor interfere with chorionic gonadotro-
pin signaling in male fetuses, producing a spectrum
of clinical disorders ranging from undervirilized




The assessment of the effect of an isolated loss of
luteinizing hormone signaling on male sexual mat-
uration has been a challenge, since inactivating mu-
tations of the luteinizing hormone beta-subunit
gene are exceptionally rare.
A previous report describes a 17-year-old boy
discussion
 
Figure 3. Lack of Alpha–Beta Heterodimerization in Cells Transfected with the Gly36Asp Mutation of the Luteinizing Hor-
mone Beta Subunit.
 
The wild-type beta subunit and the Gly36Asp mutation are both correctly synthesized in 293T cells transiently transfect-
ed with 6xHis-tagged beta-subunit expression vectors (Panel A). Immunodetection with an anti-6xHis antibody reveals 
bands of the expected size (about 18 kD) for the glycosylated form of this subunit, and no band is detectable in the 
mock-transfected cells. Panel B shows alpha–beta heterodimer formation in 293T cells that were cotransfected with the 
V5-tagged alpha subunit and either the mutant or wild-type 6xHis-tagged beta-subunit expression vectors. Immunopre-
cipitation with an anti-V5 antibody recognizing the V5-tagged alpha subunit was followed by immunoblotting with an an-
tihistidine antibody recognizing the 6xHis-tagged beta subunit. Coprecipitation of the alpha and beta subunits occurred 
in cells cotransfected with the wild-type beta subunit but not in the mutant beta subunit or in the mock-transfected cells. 
Panel C shows the correct production of the alpha subunit (expected size, about 22 kD) in cotransfected 293T cells, as 
detected by Western blotting. Panel D shows the reciprocal format of the immunoprecipitation and immunoblotting ex-
periment shown in Panel B; cell extracts were immunoprecipitated with the anti-6xHis antibody and then subjected to 
immunoblotting with the anti-V5 antibody. The alpha subunit was detected only in cells cotransfected with the wild-type 
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who presented with delayed puberty, elevated lute-
inizing hormone levels, and undetectable testoster-





 In that patient, a
missense mutation encoding a substitution of argi-
nine for glutamine at position 54 of the luteinizing
hormone beta-subunit gene (Gln54Arg) rendered
luteinizing hormone biologically inactive by impair-
ing the binding of the heterodimeric hormone to its
receptor.
In our patient, the Gly36Asp mutation of the
luteinizing hormone beta subunit abolished both
immunologic and biologic activities of luteinizing
hormone through a failure of alpha–beta hetero-
dimerization. This mutation disrupted a cystine





 The cystine knot motif
contains an eight-amino-acid ring with two di-





 The amino acid sequence CAGYC is
crucial to the formation of this ring in human glyco-
protein hormone beta subunits, since the conserved





 Amino acid substitu-






analogous glycine-to-arginine substitution in the
CAGYC region of the thyrotropin beta-subunit gene
prevents heterodimerization of thyrotropin, result-








 free luteinizing hormone beta subunits
are inefficiently secreted, and alpha–beta dimeriza-





 The absence of circulating
intact luteinizing hormone or free luteinizing hor-





 In contrast, luteinizing hormone





 Together, these findings suggest
that in nonadenomatous tissue, the secretion of lu-
teinizing hormone is dependent on adequate het-
erodimerization.
Both mutations in luteinizing hormone beta sub-
units that have been described to date abolished the
bioactivity of luteinizing hormone, although by
somewhat different mechanisms. Together, the
phenotypes of these two patients provide important
information on the role of luteinizing hormone in
postnatal male sexual differentiation and matura-
tion. Both patients were phenotypically male at
birth, with descended testes, confirming that lutein-
izing hormone is not necessary for normal mascu-
linization in utero and providing evidence of the role
of chorionic gonadotropin in directing fetal testic-





sponse to the administration of chorionic gonado-
tropin, our patient had an increased testicular
volume and an enhanced production of testoster-
one, suggesting that the persistent fetal Leydig
cells observed in the testicular-biopsy specimen re-
mained capable of steroidogenesis. These observa-
tions are generally consistent with recent data from
studies of luteinizing hormone–receptor knockout
mice (LuRKO), which are phenotypically normal at





 Caution is required when comparing data
from mice with data from humans, however, since
mice lack chorionic gonadotropin, indicating an
alternative pathway for murine Leydig-cell devel-
opment in utero. Both our patient and the one de-




 had arrested spermato-
genesis at diagnosis, suggesting that luteinizing
hormone signaling and high levels of intratesticu-
lar testosterone are not absolutely essential for some
degree of spermatogenesis to take place. This ob-
servation could account for the high rate of failure




Supported by grants (32-00B0-100 858/1, to Dr. F. Pralong, and
32-064 107.00, to Dr. R. Gaillard) from the Swiss National Science
Foundation.
We are indebted to Dr. G. Hennen and G. Pirens of Biocode-Hycel
in Liege, Belgium, for the assay for the luteinizing hormone beta
subunit; to Dr. J. Elion of Hôpital Robert-Debré in Paris for help in
genetic analyses; to M.J. Voirol for technical laboratory support; and
to Dr. A. Thiry at the University of Liege, Belgium, for interesting






Achermann JC, Jameson JL. Fertility and






Themmen APN, Huhtaniemi IT. Muta-
tions of gonadotropins and gonadotropin
receptors: elucidating the physiology and
pathophysiology of pituitary-gonadal func-




Alevizaki M, Huhtaniemi I. Structure-
function relationships of glycoprotein hor-
mones: lessons from mutations and poly-
morphisms of the thyrotropin and gonado-





Philip M, Arbelle JE, Segev Y, Parvari R.
Male hypogonadism due to a mutation in the









Lindstedt G, Nyström E, Matthews C,
Ernest I, Janson PO, Chatterjee K. Follitropin





 gene mutation: a syndrome of normal
puberty and virilization but underdeveloped
testicles with azoospermia, low FSH but high
lutropin and normal serum testosterone con-





Matthews CH, Borgato S, Beck-Peccoz P,
et al. Primary amenorrhoea and infertility due
Copyright © 2004 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org on March 8, 2010 . For personal use only. No other uses without permission. 






















Layman LC, Lee E-J, Peak DB, et al. De-
layed puberty and hypogonadism caused by










Axelrod L, Neer RM, Kliman B. Hypo-
gonadism in a male with immunologically
active, biologically inactive luteinizing hor-
mone: an exception to a venerable rule.




Weiss J, Axelrod L, Whitcomb RW, Har-
ris PE, Crowley WF, Jameson JL. Hypogo-
nadism caused by a single amino acid sub-




 subunit of luteinizing




Garcia-Campayo V, Boime I. Novel re-





Lejeune H, Habert R, Saez JM. Origin,
proliferation and differentiation of Leydig




Berthezéne F, Forest MG, Grimaud JA,
Claustrat B, Mornex R. Leydig-cell agenesis:
a cause of male pseudohermaphroditism.




Vitt UA, Hsu SY, Hsueh AJW. Evolution
and classification of cystine knot-containing
hormones and related extracellular signaling




Sun PD, Davies DR. The cystine-knot
growth-factor superfamily. Annu Rev Bio-




Darling RJ, Wilken JA, Miller-Lindholm
AK, et al. Functional contributions of non-
cysteine residues within the cystine knots of
human chorionic gonadotropin subunits.




Darling RJ, Ruddon RW, Perini F, Be-
dows E. Cystine knot mutations affect the





unit: differential secretion and assembly of





Hayashizaki Y, Hiraoka Y, Endo Y, Miyai
K, Matsubara K. Thyroid-stimulating hor-
mone (TSH) deficiency caused by a single
base substitution in the CAGYC region of
the beta-subunit. EMBO J 1989;8:2291-6.




Matzuk MM, Spangler MM, Camel M,
Suganuma N, Boime I. Mutagenesis and
chimeric genes define determinants in the
beta subunits of human chorionic gonado-
tropin and lutropin for secretion and assem-




Corless CL, Bielinska M, Ramabhadran
TV, et al. Gonadotropin alpha subunit: differ-
ential processing of free and combined forms
in human trophoblast and transfected mouse




Daneshdoost L, Gennarelli TA, Bashey
HM, et al. Recognition of gonadotroph ade-





Zhang FP, Poutanen M, Wilbertz J, Huh-
taniemi I. Normal prenatal but arrested
postnatal sexual development of luteinizing





Zhang FP, Pakarainen T, Zhu F, Pou-
tanen M, Huhtaniemi I. Molecular character-
ization of postnatal development of testicu-
lar steroidogenesis in luteinizing hormone





Zhang FP, Pakarainen T, Poutanen M,
Toppari J, Huhtaniemi I. The low gonado-
tropin-independent constitutive production
of testicular testosterone is sufficient to
maintain spermatogenesis. Proc Natl Acad




Anderson RA, Baird DT. Male contra-
ception. Endocr Rev 2002;23:735-62.
 










 editorial office invites applications for a one-year 
research fellowship beginning in July 2005 from individuals at any 









 but is expected in addition to have his or her own inde-
pendent projects. Please send curriculum vitae and research in-
terests to the Editor-in-Chief, 10 Shattuck St., Boston, MA 02115 
(fax, 617-739-9864), by January 15, 2005.
Copyright © 2004 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org on March 8, 2010 . For personal use only. No other uses without permission. 
